A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

More than 200 lawsuits demand warnings on Gardasil labels about an autoimmune disease called Postural Orthostatic Tachycardia Syndrome, or POTS, and Primary Ovarian Insufficiency, or POI ...

The decision made public on Tuesday by U.S. District Judge Kenneth Bell in Charlotte, North Carolina covers more than 200 cases in the so-called multidistrict litigation. Plaintiffs argued Merck ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks.

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Furthermore, Fiverr diligently cut costs and expenses and has now managed green on the bottom line for two consecutive years.

GSK’s restructuring of its distribution deal for its shingles vaccine Shingrix in December 2024, and MSD’s decision to pause sales of its blockbuster human papillomavirus (HPV) vaccine Gardasil until ...

Gardasil 9 is the only HPV vaccine used in the U.S., and it’s also one of the only vaccines on the market that actually prevents cancer. That’s because HPV is behind nearly all cervical cancer ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

In its Q2 2024 earnings, MSD announced that sales for Gardasil were 17% lower (18% in exchange) compared to the previous year. At the time, the company attributed this to broader market headwinds ...